Zoetis (ZTS) announced that the European Commission has granted the company marketing authorization for Portela, making it the first monoclonal antibody therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis in cats.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis Appoints Stephanie Tilenius to Board of Directors
- Zoetis price target lowered to $158 from $165 at UBS
- Zoetis announces Health Canada approval for Lenivia
- Buy Rating on Zoetis: Strategic Initiatives and Long-term Growth Potential Amid Short-term Challenges
- Zoetis’s Strategic Launch of Innovative Monoclonal Antibodies for Osteoarthritic Pain Management